Experimental drug combo aims to outsmart recurrent ovarian cancer

NCT ID NCT02627443

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-phase trial tests whether adding an experimental drug called berzosertib to standard chemotherapy (carboplatin and gemcitabine) can better treat ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 adults with platinum-sensitive disease. The main goal is to find the safest dose and watch for side effects, while also tracking how well the tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Berzosertib (M6620, VX-970) combined with carboplatin and gemcitabine hydrochloride
What this could lead to: If it works, this could point toward a more effective treatment for recurrent ovarian, peritoneal, or fallopian tube cancer that has spread.
What could go wrong: This is a very early Phase 1 trial with only 35 participants, focused on safety and dosing. It is too small and early to know if the combination works better than standard chemo, and side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE ENDOMETRIOID FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian carcinoma ovarian endometrial cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma primary peritoneal serous/papillary carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC FALLOPIAN TUBE CARCINOMA METASTATIC OVARIAN CARCINOMA METASTATIC PRIMARY PERITONEAL CARCINOMA OVARIAN ENDOMETRIOID TUMOR OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA PLATINUM-SENSITIVE OVARIAN CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA STAGE IV FALLOPIAN TUBE CANCER AJCC V6 AND V7 STAGE IV OVARIAN CANCER AJCC V6 AND V7 STAGE IV PRIMARY PERITONEAL CANCER AJCC V7

Contacts and locations

Locations

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
UF Health Cancer Institute - Gainesville

Gainesville, Florida, 32610, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.